Search
Search Results
-
Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS)
Chronic eosinophilic leukemia-not otherwise specified (CEL-NOS) is a rare, aggressive, fatal disease characterized by blood eosinophilia and...
-
T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature
In the 2022, WHO and ICC classifications, myeloid/lymphoid neoplasms with eosinophilia (M/LN-eo) and tyrosine kinase gene fusions represent rare...
-
Updates on eosinophilic disorders
This review addresses changes and updates in eosinophilic disorders under the International Consensus Classification (ICC). The previous category of...
-
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies
PurposeHypereosinophilia represents a heterogenous group of severe medical conditions characterized by elevated numbers of eosinophil granulocytes in...
-
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma
Purpose of ReviewWe review the recent practice-changing trials of anti-CD19 chimeric antigen receptor (CAR) T cell therapies in large B cell lymphoma...
-
Clinicopathological differences in focal segmental glomerulosclerosis depending on the accompanying pathophysiological conditions in renal allografts
Primary focal segmental glomerulosclerosis (FSGS) is thought to be caused by circulating factors leading to podocytopathy, whereas segmental...
-
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas...
-
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T...
-
A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma
BackgroundIn this ever-expanding treatment landscape, there is a lack of consolidated health-related quality of life (HRQOL) outcomes and utility...
-
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents
Multiple Myeloma remains incurable, and there is a need for therapies with novel mechanisms of action. Recently, B cell maturation antigen targeted...
-
-
International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
The recently published International Consensus Classification (ICC) of myeloid neoplasms summarized the results of an in-depth effort by...
-
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data guiding management are limited. We describe outcomes and...
-
A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis
Axicabtagene ciloleucel (axi-cel) is an autologous, CD19-targeting chimeric antigen receptor T‑cell therapy. We recently reported the 3-month...
-
Engineered T Cells: CAR T Cell Therapy and Beyond
Purpose of ReviewThis article reviews the current data and future directions of engineered T cell therapies in non-Hodgkin lymphomas.
... -
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
BackgroundThere are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or...
-
WHO-Klassifikation 2022 chronischer myeloproliferativer Erkrankungen
BackgroundHuman neoplasms of various organ systems are being hierarchically cataloged by the World Health Organization (WHO) in a unified relational...
-
-
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience...
-
Eosinophilie: hypereosinophiles Syndrom versus eosinophile Granulomatose mit Polyangiitis
Hypereosinophilic syndrome (HES) is defined as a peripheral eosinophil count of > 1500/μl (assessed twice at an interval of ≥ 2 weeks) and an...
